ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 02 Jan 2024
Last Updated on 02 Jan 2024
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:

Faricimab 6 mg/0.05 mL vial for treating adults with visual impairment due to:

  • diabetic macular oedema; and
  • neovascular (wet) age-related macular degeneration.

Funding status

Faricimab 6 mg/0.05 mL vial is recommended for inclusion on the MOH Medication Assistance Fund (MAF) for the abovementioned indications from 1 March 2024.

MAF assistance does not apply to any formulations or strengths of aflibercept for treating diabetic macular oedema or neovascular age-related macular degeneration.



Anti-vascular endothelial growth factors for treating diabetic macular oedema and age-related macular degeneration (Published 2 Jan 2024) PES Aflibercept and faricimab for treating diabetic macular oedema and age-related macular degeneration (Published 2 Jan 2024)